1. Bennardello F, Coluzzi S, Curciarello G, Todros T, Villa S. Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) and Italian Society of Gynaecology and Obstetrics (SIGO) working group. Recommendations for the prevention and treatment of haemolytic disease of the foetus and newborn. Blood Transfus 2015;13:109-134. PMID:
25633877.
3. Agarwal K, Rana A, Ravi AK. Treatment and prevention of Rh isoimmunization. J Fetal Med 2014;1:81-88.
4. Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program 2015;2015:146-151. PMID:
26637714.
5. Qureshi H, Massey E, Kirwan D, Davies T, Robson S, White J, et al. BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn. Transfus Med 2014;24:8-20. PMID:
25121158.
7. Minon JM, Gerard CH, Chantraine F, Nisolle M. Anti-D prophylaxis reviewed in the erea of foetal RHD genotyping. J Blood Disord Transfus 2015;6:1-6.
8. Brinc D, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am Soc Hematol Educ Program 2009;2009:185-191.
9. Holzlöhner P, Hanack K. Generation of murine monoclonal antibodies by hybridoma technology. J Vis Exp 2017;119:e54832.
12. Crowther C, Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2000;CD000021. PMID:
10796089.
13. McBain RD, Crowther CA, Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev 2015;CD000020. PMID:
26334436.
14. Dajak S, Roje D, Hašpl ŽH, Maglić PE. The importance of antenatal prevention of RhD immunisation in the first pregnancy. Blood Transfus 2014;12:410-415. PMID:
24887219.
15. US Food and Drug Administration. Assay development and validation for immunogenicity testing of therapeutic protein products [Internet]. Silver Spring (MD): USFDA Draft Guidance for Industry; c2016. cited 2019 Jan 17. Available from:
https://www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf.
16. Costumbrado J, Ghassemzadeh S. Incompatibility. In: Abai B, editors. StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
17. Zipursky A, Bhutani VK, Odame I. Rhesus disease: a global prevention strategy. Lancet Child Adolesc Health 2018;2:536-542. PMID:
30169325.
18. Reverberi R. The persistence of red cell alloantibodies. Blood Transfus 2008;6:225-234. PMID:
19112738.
19. Fiala C, Fux M, Gemzell Danielsson K. Rh-prophylaxis in early abortion. Acta Obstet Gynecol Scand 2003;82:892-903. PMID:
12956838.
20. Howard HL, Martlew VJ, McFadyen IR, Clarke CA. Preventing Rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed? Br J Obstet Gynaecol 1997;104:37-41. PMID:
8988694.
21. Hong F, Ruiz R, Price H, Griffiths A, Malinoski F, Woloski M. Safety profile of WinRho anti-D. Semin Hematol 1998;35:9-13.
22. Rutkowski K, Nasser SM. Management of hypersensitivity reactions to anti-D immunoglobulin preparations. Allergy 2014;69:1560-1563. PMID:
25066207.